SOX2 and lung adenocarcinoma: The differential expression of HDAC11 is particularly interesting and deserves to be explored in further studies, given the recently reported effect of HDAC11-specific inhibitors in eliminating treatment-resistant lung adenocarcinoma cells by targeting SOX2 [47], which is amplified in the NCCIT cell line [48].